(Q36577073)

15 August 2017

1 reference

title

Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection (English)

1 reference

15 August 2017

Usha Panchapakesan

1

1 reference

15 August 2017

Xin-Ming Chen

series ordinal

2

1 reference

15 August 2017

Carol A Pollock

series ordinal

3

1 reference

15 August 2017

publication date

1 November 2005

1 reference

Nature Clinical Practice Nephrology

15 August 2017

published in

1 reference

15 August 2017

volume

1

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

33-43

1 reference

Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Tubulointerstitial changes as a major determinant in the progression of renal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Biochemistry and molecular cell biology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Transcriptional activation of transforming growth factor-beta1 in mesangial cell culture by high glucose concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-beta bioactivity in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

The nuclear receptor ligand-binding domain: structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Albumin and glucose effects on cell growth parameters, albumin uptake and Na(+)/H(+)-exchanger Isoform 3 in OK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Effects of pathophysiological concentrations of albumin on NHE3 activity and cell proliferation in primary cultures of human proximal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

c-Fos-driven transcriptional activation of transforming growth factor β-1: inhibition of high glucose-induced promoter activity by thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Anti-inflammatory effect of PPARgamma in cultured human mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome Proliferator-Activated Receptor γ Agonist Provides Superior Renal Protection versus Angiotensin-Converting Enzyme Inhibition in a Rat Model of Type 2 Diabetes with Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)? activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Effects of different PPARgamma-agonists on MCP-1 expression and monocyte recruitment in experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Activation of PPARdelta alters lipid metabolism in db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical mode

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Rosiglitazone reduces urinary albumin excretion in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

GI262570, a peroxisome proliferator-activated receptor {gamma} agonist, changes electrolytes and water reabsorption from the distal nephron in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy-Delta12,14-prostaglandin J2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated rece

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

PPARgamma ligands attenuate mesangial contractile dysfunction in high glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Expression and function of PPARgamma in rat and human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Peroxisome proliferator-activated receptor gamma1 (PPARgamma1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

Integrated actions of transforming growth factor-beta1 and connective tissue growth factor in renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

The peroxisome proliferator-activated receptor interacts with the retinoid X receptor in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Advanced glycation end product-induced peroxisome proliferator-activated receptor gamma gene expression in the cultured mesangial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Expression of macrophage (Mphi) scavenger receptor, CD36, in cultured human aortic smooth muscle cells in association with expression of peroxisome proliferator activated receptor-gamma, which regulates gain of Mphi-like phenotype in vitro, and its

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated rec

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEPH0029

7 January 2021

Identifiers

DOI

10.1038/NCPNEPH0029

1 reference

15 August 2017

1 reference